EML4 and neoplasm: The inhibition of tumor derived cell line from our EML4-ALK CRC patient by two separate ALK inhibitors is encouraging and provides pre-clinical rationale for enrolling ALK-rearranged CRC patients onto clinical trials with ALK inhibitor.